Brokerages expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings per share of ($0.05) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at ($0.17). Conatus Pharmaceuticals posted earnings of ($0.31) per share in the same quarter last year, which indicates a positive year over year growth rate of 83.9%. The business is expected to issue its next quarterly earnings results after the market closes on Wednesday, November 1st.
Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.02). The firm had revenue of $10.00 million during the quarter, compared to analyst estimates of $9.33 million. During the same period in the previous year, the firm posted ($0.30) earnings per share.
Several brokerages recently issued reports on CNAT. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Seaport Global Securities restated a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Finally, Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $16.17.
Shares of Conatus Pharmaceuticals (NASDAQ CNAT) traded down 0.43% during trading on Friday, hitting $4.68. The stock had a trading volume of 13,182 shares. The stock’s 50-day moving average is $5.40 and its 200-day moving average is $5.77. The stock’s market capitalization is $140.42 million. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC raised its position in Conatus Pharmaceuticals by 641.1% during the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after purchasing an additional 949,785 shares in the last quarter. Vanguard Group Inc. raised its position in Conatus Pharmaceuticals by 31.2% during the second quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after purchasing an additional 239,373 shares in the last quarter. State Street Corp acquired a new position in Conatus Pharmaceuticals during the second quarter valued at approximately $2,092,000. Northern Trust Corp raised its position in Conatus Pharmaceuticals by 640.6% during the second quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 257,030 shares in the last quarter. Finally, Numeric Investors LLC acquired a new position in Conatus Pharmaceuticals during the second quarter valued at approximately $1,620,000. Institutional investors and hedge funds own 33.06% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Conatus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Conatus Pharmaceuticals Inc. and related companies.